Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Betamethasone
Drug ID BADD_D00260
Description Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties.[A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.[A192444] Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.[A192444]
Indications and Usage As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses.[L11991,L10782,L11997] Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis.[L12000] The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.[L11994]
Marketing Status approved; vet_approved
ATC Code A07EA04; C05AA05; D07AC01; D07XC01; H02AB01; R01AD06; R03BA04; S01BA06; S01CB04; S02BA07; S03BA03
DrugBank ID DB00443
KEGG ID D00244
MeSH ID D001623
PubChem ID 9782
TTD Drug ID D0CW1P
NDC Product Code 52128-166; 22552-0030; 57582-007; 64958-0012
UNII 9842X06Q6M
Synonyms Betamethasone | Flubenisolone | Betadexamethasone | Celestona | Cellestoderm | Celeston | Celestone
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 378-44-9
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertrophic cardiomyopathy02.04.01.002; 03.07.07.005---
Hypokalaemic syndrome14.05.03.003---
Hypopituitarism05.03.02.001--
Hypotension24.06.03.002--
Impaired healing08.03.02.001---
Increased appetite08.01.09.027; 14.03.01.003---
Increased insulin requirement05.06.01.006; 14.06.01.006---
Infection11.01.08.002---
Infection susceptibility increased10.02.01.046; 11.01.08.004---
Inflammatory bowel disease07.08.01.016---
Influenza like illness08.01.03.010--
Injection site bruising08.02.03.042; 12.07.03.042; 23.03.11.015; 24.07.06.017---
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.015---
Injection site haemorrhage08.02.03.005; 12.07.03.005; 24.07.01.010---
Injection site pain08.02.03.010; 12.07.03.011---
Injury12.01.08.004---
Insomnia17.15.03.002; 19.02.01.002--
Intracranial pressure increased17.07.02.002---
Intraocular pressure increased13.07.04.002---
Joint stiffness15.01.02.003---
Joint swelling15.01.02.004---
Lacrimation increased06.08.02.004--
Large intestine perforation07.04.06.005; 12.02.03.005--
Leukoderma23.05.02.001---
Loss of consciousness17.02.04.004---
Lymphadenopathy01.09.01.002---
Macule23.03.03.037---
Malaise08.01.01.003--
Meningitis11.01.03.001; 17.06.03.001--
Menstruation irregular05.05.01.008; 21.01.01.005--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages